@inproceedings{inproceedings, title  = {{Vandetanib, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (HER1), Potentiates Anti-Tumor Effects of Combined Endocrine and Trastuzumab Treatment in Estrogen Receptor-Positive (ER+)/HER2-Overexpressing Xenografts.}},

 url = {{}},

 year = {{2009}},

 month = {{1}},

 author = {{Malorni L and Hilsenbeck SG and Soliz RD and Ward RM and Ryan AJ and Osborne KC and Schiff R}},

 volume = {{69}},

 journal = {{CANCER RESEARCH}},

 issue = {{24}},

 pages = {{808S-808S}},

 note = {{Accessed on 2024/12/22}}}